Russell Investments Group Ltd. Has $1.74 Million Stock Holdings in Akebia Therapeutics, Inc. (NASDAQ:AKBA)

Russell Investments Group Ltd. grew its position in Akebia Therapeutics, Inc. (NASDAQ:AKBA) by 1.5% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 459,080 shares of the biopharmaceutical company’s stock after buying an additional 6,671 shares during the period. Russell Investments Group Ltd.’s holdings in Akebia Therapeutics were worth $1,738,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Morgan Stanley grew its position in shares of Akebia Therapeutics by 1,182.3% in the 1st quarter. Morgan Stanley now owns 3,340,710 shares of the biopharmaceutical company’s stock valued at $11,308,000 after purchasing an additional 3,080,193 shares during the period. Citigroup Inc. boosted its holdings in shares of Akebia Therapeutics by 2,488.7% in the first quarter. Citigroup Inc. now owns 1,134,548 shares of the biopharmaceutical company’s stock valued at $3,840,000 after buying an additional 1,090,721 shares during the period. BlackRock Inc. increased its position in shares of Akebia Therapeutics by 8.5% during the first quarter. BlackRock Inc. now owns 12,368,986 shares of the biopharmaceutical company’s stock worth $41,868,000 after acquiring an additional 971,438 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Akebia Therapeutics by 39.2% during the first quarter. Dimensional Fund Advisors LP now owns 2,432,259 shares of the biopharmaceutical company’s stock worth $8,231,000 after acquiring an additional 684,955 shares during the period. Finally, Rafferty Asset Management LLC lifted its position in Akebia Therapeutics by 213.9% in the 1st quarter. Rafferty Asset Management LLC now owns 922,954 shares of the biopharmaceutical company’s stock valued at $3,124,000 after acquiring an additional 628,925 shares in the last quarter. Institutional investors and hedge funds own 60.57% of the company’s stock.

Separately, Zacks Investment Research downgraded Akebia Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, August 11th.

NASDAQ AKBA opened at $2.90 on Friday. The firm’s 50 day moving average is $2.77 and its 200-day moving average is $3.17. The company has a quick ratio of 1.77, a current ratio of 2.00 and a debt-to-equity ratio of 0.55. The company has a market capitalization of $506.16 million, a PE ratio of -1.46 and a beta of 1.71. Akebia Therapeutics, Inc. has a 12-month low of $2.09 and a 12-month high of $5.14.

Akebia Therapeutics (NASDAQ:AKBA) last issued its quarterly earnings results on Wednesday, August 4th. The biopharmaceutical company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.21). Akebia Therapeutics had a negative return on equity of 125.60% and a negative net margin of 135.00%. As a group, sell-side analysts expect that Akebia Therapeutics, Inc. will post -1.46 EPS for the current year.

About Akebia Therapeutics

Akebia Therapeutics, Inc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat.

Featured Article: What moving averages are used to define a golden cross?

Want to see what other hedge funds are holding AKBA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Akebia Therapeutics, Inc. (NASDAQ:AKBA).

Institutional Ownership by Quarter for Akebia Therapeutics (NASDAQ:AKBA)

Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.